A randomized double blind parallel group multicenter multinational study to assess glycemic control with rimonabant in comparison with glimepiride over 1 year in overweight/obese type 2 diabetic patients not adequately controlled with metformin
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Rimonabant (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ALLEGRO
- Sponsors Sanofi
- 24 Jun 2009 Sanofi-Synthelabo added as trial sponsor and affiliate as reported by Clinical Trials Registry - India
- 24 Jun 2009 New source identified and integrated (Clinical Trials Registry - India).
- 23 Jun 2009 Actual number of patients (508) added, additional trial locations India and Puerto Rico identified as reported by ClinicalTrials.gov.